81.91k followers • 22 symbols Watchlist by Yahoo Finance
Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AB InBev (BUD) is poised for growth in second-quarter 2019, owing to strong sales trend and persistent strength in global brands. However, weakness in some markets and soft beer volume may affect results.
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Medical cannabis is gaining widespread acceptance due to increased awareness. Several countries are looking into cannabis as an alternative for existing medicine.
FT premium subscribers can click here to receive Due Diligence every day by email. One thing to start: London’s top corporate lawyers took home record pay last year. Get the details here . Now on to the ...
In the latest trading session, Canopy Growth Corporation (CGC) closed at $34.86, marking a -1.76% move from the previous day.
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
On July 19, Tilray was trading at a forward EV-to-sales multiple of 12.1x. The company was still trading at a premium to the peer median at 6.0x.
A big, cold beer, as the famous Australian lager ad puts it, is the answer to a hard-earned thirst. It is less enticing to those drenched in debt, even if their taste for the amber nectar has made them the world’s biggest brewer. Asahi investors have little reason to crack a tinnie.
Japanese brewer Asahi lost more than $2bn of its market value on Monday as investors fretted about its debt load following an $11.3bn deal to buy Anheuser-Busch InBev’s Australian operations. Asahi had moved swiftly to buy Carlton & United Breweries from AB InBev after the world’s largest brewer looked to raise cash in the wake of the aborted initial public offering of its Asian business. On top of fresh debt concerns, Japan’s largest brewer has warned investors that it will issue up to $1.9bn in new equity to finance the latest acquisition, which will result in an 8.7 per cent dilution.